Phase 3 study of new dry eye treatment shows promising top-line results

Top-line results from OPUS-2, a phase 3 efficacy and safety study of 5.0% lifitegrast ophthalmic solution, describe statistically significant improvement in patient-reported dry eye symptoms, according to a Shire press release. At week 12, lifitegrast met the co-primary endpoint for change in Eye Dryness Score at 12 weeks, but did not meet the other primary endpoint for change in sign of inferior corneal staining score using fluorescein staining compared with placebo, according to the release. Lifitegrast is a small-molecule integrin antagonist and a preservative-free topical eye solution designed to treat (Read more...)

Full Story →